BACKGROUND: Vascular α1 and α2 adrenergic receptors mediate vasoconstriction and are major determinants of peripheral vascular tone. There is a wide variability in vasoconstrictor sensitivity to α1 and α2 adrenergic receptor agonists among individuals. In previous studies, this variability was not explained by identified α1 and α2 adrenergic receptor genetic variants. Thus, we hypothesized that adrenergic vasoconstrictor sensitivity is determined by shared constrictor mechanisms downstream of the individual receptors and that α1 and α2 adrenergic receptor-mediated vasoconstrictor sensitivity would therefore be correlated. METHODS: Dorsal hand vein responses to increasing doses of the α1 adrenergic receptor agonist phenylephrine (12-12 000 ng/min) and the α2 adrenergic receptor agonist dexmedetomidine (0.01-100 ng/min) were measured in healthy individuals using a linear variable differential transformer. From individual dose-response curves, we calculated the dose of phenylephrine and dexmedetomidine that produced 50% (ED50) of maximum venoconstriction (Emax) for each patient. We examined the correlation between phenylephrine and dexmedetomidine ED50 and Emax before and after adjustment for covariates (age, sex, ethnicity, BMI, blood pressure, heart rate, and baseline plasma norepinephrine concentrations). RESULTS: In 62 patients (36 men, 34 African-American, 28 whites), the median ED50 for dexmedetomidine was 1.32 ng/min [interquartile range (IQR) 0.45-5.37 ng/min] and for phenylephrine 177.8 ng/min (IQR 40.7-436.5 ng/min). The Emax for phenylephrine was 90.8% (82.2-99.6%) and for dexmedetomidine 80.0% (64.7-95.2%). There was no correlation between individual sensitivities (ED50) to phenylephrine and dexmedetomidine, before and after adjustment for covariates (P > 0.30). CONCLUSION: Both phenylephrine and dexmedetomidine produce strong venoconstriction in the dorsal hand vein; however, there is no significant correlation between vascular sensitivity to an α1 and α2 adrenergic receptor agonist. These findings suggest the independent regulation of vascular α1 and α2 adrenergic receptor-mediated responses.
BACKGROUND: Vascular α1 and α2 adrenergic receptors mediate vasoconstriction and are major determinants of peripheral vascular tone. There is a wide variability in vasoconstrictor sensitivity to α1 and α2 adrenergic receptor agonists among individuals. In previous studies, this variability was not explained by identified α1 and α2 adrenergic receptor genetic variants. Thus, we hypothesized that adrenergic vasoconstrictor sensitivity is determined by shared constrictor mechanisms downstream of the individual receptors and that α1 and α2 adrenergic receptor-mediated vasoconstrictor sensitivity would therefore be correlated. METHODS: Dorsal hand vein responses to increasing doses of the α1 adrenergic receptor agonist phenylephrine (12-12 000 ng/min) and the α2 adrenergic receptor agonist dexmedetomidine (0.01-100 ng/min) were measured in healthy individuals using a linear variable differential transformer. From individual dose-response curves, we calculated the dose of phenylephrine and dexmedetomidine that produced 50% (ED50) of maximum venoconstriction (Emax) for each patient. We examined the correlation between phenylephrine and dexmedetomidine ED50 and Emax before and after adjustment for covariates (age, sex, ethnicity, BMI, blood pressure, heart rate, and baseline plasma norepinephrine concentrations). RESULTS: In 62 patients (36 men, 34 African-American, 28 whites), the median ED50 for dexmedetomidine was 1.32 ng/min [interquartile range (IQR) 0.45-5.37 ng/min] and for phenylephrine 177.8 ng/min (IQR 40.7-436.5 ng/min). The Emax for phenylephrine was 90.8% (82.2-99.6%) and for dexmedetomidine 80.0% (64.7-95.2%). There was no correlation between individual sensitivities (ED50) to phenylephrine and dexmedetomidine, before and after adjustment for covariates (P > 0.30). CONCLUSION: Both phenylephrine and dexmedetomidine produce strong venoconstriction in the dorsal hand vein; however, there is no significant correlation between vascular sensitivity to an α1 and α2 adrenergic receptor agonist. These findings suggest the independent regulation of vascular α1 and α2 adrenergic receptor-mediated responses.
Authors: J L González-Trápaga; R A Nelesen; J E Dimsdale; P J Mills; B Kennedy; R J Parmer; M G Ziegler Journal: Life Sci Date: 2000-05-05 Impact factor: 5.037
Authors: Mordechai Muszkat; Daniel Kurnik; Gbenga G Sofowora; Joseph Solus; Hong-Guang Xie; Paul A Harris; Scott M Williams; Alastair J J Wood; C Michael Stein Journal: J Hypertens Date: 2010-02 Impact factor: 4.844
Authors: Gbenga G Sofowora; Victor Dishy; Ruth Landau; Hong-Guang Xie; Harish C Prasad; Daniel W Byrne; Richard M Smiley; Richard B Kim; Alastair J J Wood; C Michael Stein Journal: Clin Pharmacol Ther Date: 2004-06 Impact factor: 6.875
Authors: Jacqueline Querino Alves; Laena Pernomian; Cássia Dias Silva; Mayara Santos Gomes; Ana Maria de Oliveira; Roberto Santana da Silva Journal: RSC Med Chem Date: 2020-02-27
Authors: Jussi P Posti; Perttu Salo; Saku Ruohonen; Laura Valve; Mordechai Muszkat; Gbenga G Sofowora; Daniel Kurnik; C Michael Stein; Markus Perola; Mika Scheinin; Amir Snapir Journal: Pharmacogenet Genomics Date: 2013-03 Impact factor: 2.089
Authors: Abiodun Adefurin; Laxmi V Ghimire; Utkarsh Kohli; Mordechai Muszkat; Gbenga G Sofowora; Sachin Y Paranjape; C Michael Stein; Daniel Kurnik Journal: Hypertension Date: 2013-02-11 Impact factor: 10.190
Authors: A Adefurin; L V Ghimire; U Kohli; M Muszkat; G G Sofowora; C Li; S Y Paranjape; C M Stein; D Kurnik Journal: Pharmacogenomics J Date: 2014-11-25 Impact factor: 3.550
Authors: A Adefurin; L V Ghimire; U Kohli; M Muszkat; G G Sofowora; C Li; R T Levinson; S Y Paranjape; C M Stein; D Kurnik Journal: Pharmacogenomics J Date: 2016-04-19 Impact factor: 3.550
Authors: Samantha F Holliday; Sandra L Kane-Gill; Philip E Empey; Mitchell S Buckley; Pamela L Smithburger Journal: ScientificWorldJournal Date: 2014-01-16